A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer by Willeke, F et al.
A phase II study of capecitabine and irinotecan in combination
with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant
treatment of locally advanced rectal cancer
F Willeke
1,5, K Horisberger
1,5, U Kraus-Tiefenbacher
2, F Wenz
2, A Leitner
3, A Hochhaus
3, R Grobholz
4,
A Willer
3,GK a ¨hler
1, S Post
1 and R-D Hofheinz*,3
1Chirurgische Klinik, Medizinische Fakulta ¨t Mannheim der Universita ¨t Heidelberg, Mannheim, Germany;
2Klinik fu ¨r Strahlentherapie und Radioonkologie,
Medizinische Fakulta ¨t Mannheim der Universita ¨t Heidelberg, Mannheim, Germany;
3Onkologisches Zentrum, III. Medizinische Klinik, Medizinische
Fakulta ¨t Mannheim der Universita ¨t Heidelberg, Mannheim, Germany;
4Institut fu ¨r Pathologie, Medizinische Fakulta ¨t Mannheim der Universita ¨t
Heidelberg, Mannheim, Germany
We sought to evaluate the efficacy and safety data of a combination regimen using weekly irinotecan in combination with
capecitabine and concurrent radiotherapy (CapIri-RT) as neoadjuvant treatment in rectal cancer in a phase-II trial. Patients with rectal
cancer clinical stages T3/4 Nx or Nþ were recruited to receive irinotecan (50mgm
 2 weekly) and capecitabine (500mgm
 2 bid
days 1–38) with a concurrent RT dose of 50.4Gy. Surgery was scheduled 4–6 weeks after the completion of chemoradiation. A
total of 36 patients (median age 62 years; m/f: 27:9) including three patients with local recurrence were enclosed onto the trial. The
median distance of the tumour from the anal verge was 5cm. The main toxicity observed was (NCI-CTC grades 1/2/3/4 (n)):
Anaemia 23/9/ / ; leucocytopenia 12/7/7/2, diarrhoea 13/15/4/ , nausea/vomiting 9/10/2/ , and increased activity of
transaminases 3/3/1/ . One patient had a reversible episode of ventricular fibrillation during chemoradiation, most probably
caused by capecitabine. The relative dose intensity was (median/mean (%)): irinotecan 95/91, capecitabine 100/92). Thirty-four
patients underwent surgery (anterior resection n¼25; abdomino-perineal resection n¼6; Hartmann’s procedure n¼3).
R0-resection was accomplished in all patients. Two patients died in the postoperative course from septic complications. Pathological
complete remission was observed in five out of 34 resected patients (15%), and nine patients showed microfoci of residual tumour
(26%). After a median follow-up of 28 months one patient had developed a local recurrence, and five patients distant metastases.
Three-year overall survival for all patients with surgery (excluding three patients treated for local relapse or with primary metastatic
disease) was 80%. In summary, preoperative chemoradiation with CapIri-RT exhibits promising efficacy whereas showing managable
toxicity. The local recurrence and distant failure rates observed after a median 28 months are low compared with standard
5-fluorouracil based therapy.
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Advances in surgical technique, including total mesorectal excision
and thorough pathohistological work-up of the resected specimen
have significantly improved the prognosis of patients with
localised rectal cancer during the past two decades. Nevertheless,
preoperative radiotherapy further improves local recurrence rates
(Kapiteijn et al, 2001). The German CAO/AIO/ARO-94 trial, which
compared pre- and postoperative chemoradiation in resectable
rectal cancer, established the neoadjuvant approach as a new
standard of care given it’s superiority with respect to local failure
rates and toxicity (Sauer et al, 2004). Moreover, the MRC CR07
trial, which compared short-course preoperative radiotherapy
(5 5Gy) in resectable rectal cancer with selective postoperative
chemoradiation in patients with compromised circumferential
resection margins, showed a significant reduction in local
recurrence and improved disease-free survival in favour of the
short-course preoperative radiotherapy (Sebag-Montefiore et al,
2006). Finally, both the EORTC 22921 and the FFCD 9203 trials
demonstrated that adding 5-fluorouracil (5-FU) to preoperative
radiotherapy further diminishes the rate of local recurrence
and increases the rate of pathological complete remissions (pCR)
(Bosset et al, 2005; Gerard et al, 2005). Thus, preoperative
5-FU-based chemoradiation has meanwhile gained a high level
of evidence in the treatment of resectable rectal cancer. More-
over, data from several single-agent chemoradiation studies
provide a clear rationale for a simplification of chemoradiotherapy
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sby the replacement of infusional 5-FU with the oral prodrug
capecitabine (Xeloda, Hoffmann-La Roche Inc., Basel, Switzerland)
(reviewed by Glynne-Jones et al, 2006).
Local recurrence appears to be now less of a problem, whereas
distant metastasis remains the most common form of treatment
failure. Intensified neoadjuvant chemoradiation using two drug-
schedules are under investigation mainly for two reasons: (i) it is
hoped that early administration of systemically effective doses of
chemotherapy might improve long-term outcome and reduce the
rate of distant failure by the early treatment of micrometastases;
(ii) intensified two drug regimen increase, the likelihood of tumour
remission (especially the pCR rate) (Hartley et al, 2005) which
might augment the chance to obtain clear circumferential margins.
Moreover, there is a strong evidence that pCR is a prognostic
factor for patients undergoing neoadjuvant chemoradiation for
rectal cancer (Roh et al, 2004; Ro ¨del et al, 2005).
The feasibility and efficacy of combinations of 5-FU or
capecitabine with newer drugs like irinotecan (Campto, Pfizer,
Karlsruhe, Germany) during neoadjuvant chemoradiotherapy
has been demonstrated in several trials (reviewed by Klautke
et al, 2005). Irinotecan has radiosensitizing properties (reviewed
by Mitchell, 2000) and is a standard for care in the first-line
treatment of metastatic colorectal cancer (eg Ko ¨hne et al, 2005). In
the phase-I trial, we established a chemoradiotherapy regimen
adding weekly irinotecan 50mgm
 2 and capecitabine (500mgm
 2
bid) to conventionally fractionated radiotherapy (CapIri-RT) for
the neoadjuvant treatment of rectal cancer (Hofheinz et al, 2005).
The tolerability was good and preliminary pCR rates were
encouraging.
The present phase-II trial sought to expand the safety and
efficacy data obtained in the dose-finding trial. Here we report on
the acute toxicity and efficacy of the CapIri-RT regimen along with
the follow-up data of 36 patients.
PATIENTS AND METHODS
Eligibility criteria
Patients with histologically confirmed locally advanced non-
metastastic rectal adenocarcinoma (cT3/4 or cTxNþ) were eligible
for entry in the study. The definition of the T category was made
by transrectal ultrasonography and pelvic computed tomographic
(CT) scans. Further inclusion criteria comprised: Eastern
Cooperative Oncology Group (ECOG) performance score p2;
age X18 years; adaequate bone marrow function (leucocyte
count 43000ml
 1, platelet count 4100000ml
 1); and adaequate
renal (serum creatinine p1.4mgdl
 1 or creatinine clearance
460mlmin
 1) and hepatic function (bilirubin p2mgdl
 1).
Patients with a history of Gilbert-Meulengracht’s disease were
excluded. Patients of childbearing potential were required to use
appropriate contraception. Patients were excluded if they suffered
from other cancers, ischaemic heart disease or had known
hypersensitivity to 5-FU and/or irinotecan.
The protocol was reviewed and approved by the local
institutional review board and the study was performed according
to the Declaration of Helsinki. All patients provided written
informed consent before entering the trial.
Pretreatment evaluation
Before study admission, all patients underwent a complete history,
physical examination, biopsy with confirmation of adeno-
carcinoma, digital rectal examination, rectoscopy, transrectal
ultrasonography, pelvic and abdominal CT scans, colonoscopy,
and chest X-rays. Since the study protocol derived from 2002,
when MRI imaging has not yet found widespread use in Germany,
MRI staging was not mandatory in this study. A full blood count
with differential and serum chemistry (including electrolytes,
creatinine, urea, uric acid, transaminases, total bilirubin, alkaline
phosphatase, and lactic dehydrogenase) was obtained within 14
days before the start of treatment. Weekly blood counts were
obtained, and serum chemistry was repeated every third week or
whenever clinically indicated.
Radiotherapy
Radiotherapy (RT) was delivered with a linear accelerator using
23MeV photons and a three-field box technique consisting of a
posterior–anterior and two lateral fields. For three-dimensional
treatment planning purposes, all patients had a CT scan in the
treatment position (prone position) using a belly board. A total
irradiation dose of 50.4Gy was given in daily fractions of 1.8Gy,
5 days a week. The clinical target volume (CTV) according to the
ICRU included the sacrum, the praesacral space and the posterior
wall of the bladder, and prostate/vagina. The common iliac lymph
nodes were included in the CTV. The upper border of the CTV was
at the L5/S1 interspace for cN0 and at L4/L5 for cNþ patients. The
lower field border was 5cm below the macroscopic tumour. After a
dose of 45Gy the small bowel was excluded and an additional dose
of 5.4Gy was given to boost the volume using a shrinking field
technique (days 36–38).
Chemotherapy
Starting at day 1 of RT, patients received capecitabine 500mgm
 2
orally bid within 30min after a meal (generally after breakfast and
dinner) for the whole time of irradiation (days 1–38), and weekly
irinotecan 50mgm
 2 beginning on day 1 of RT for 5 consecutive
weeks (days 1, 8, 15, 22, and 29) (Hofheinz et al, 2005). All patients
received standard antiemetic prophylaxis using 5-HT3 antagonists
and dexamethasone.
If a patient reported one of the following adverse events
according to National Cancer Institute common toxicity criteria
(NCI-CTC version 3.0), chemotherapy was interrupted until
adverse events had resolved to grade 0 or 1: leucocytopenia
Xgrade 2, thrombocytopenia Xgrade 2, diarrhoea Xgrade 2,
mucositis/stomatitis Xgrade 2, skin adverse events Xgrade 2, and
other adverse events 4grade 2. Treatment was resumed in these
cases with a dose reduction of 25% for both drugs (in case of hand-
foot skin reaction only capecitabine was reduced by 25%). On the
second occurrence of an adverse event Xgrade 2, the capecitabine
and irinotecan dose was to be reduced to 50% of the starting
dose (except in the case of, hand-foot skin reaction; only
capecitabine was to be reduced by 50%).
The application of postoperative adjuvant chemotherapy was
left at the discretion of the treating physician.
All effort was made to continue daily RT without interruption,
unless the patient experienced persistent or severe adverse event.
The RT schedule was not modified or interrupted, unless an
adverse event (such as a skin adverse event Xgrade 2) was related
to radiation. In these cases, RT was withheld until adverse events
resolved to grade 0 or 1.
Surgery and histopathologic examination of resected
specimen
Surgical resection (either low anterior or abdomino-perineal
resection) with total mesorectal excision (TME) was scheduled
4–6 weeks after completion of CapIri-RT. A time interval of 4–6
weeks between the termination of chemoradiotherapy and surgery
was chosen, because it is considered a standard of care by most
German centers. Pathological examination of the surgical speci-
men involved opening the specimen, identification of the former
tumour-bearing area and macroscopic description followed by
fixation in 10% neutral-buffered formalin for 24h. After fixation,
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sspecimens were processed according to standard protocols
(Compton, 2000). For obvious residual tumour, at least four
paraffin blocks were processed. If no obvious residual tumour was
present, the whole former tumour-bearing area was sliced and
embedded. The completion of TME, circumferential resection
margins, proximal and distal tumour-free margins, tumour mass,
fibrotic changes, and irradiation vasculopathy were evaluated and
semiquantitatively described whenever feasible.
Study design and data evaluation
The primary end point of this phase II study was to assess the
toxicity, efficacy (especially the pCR rate), and surgical morbidity
of the CapIri-RT regimen (capecitabine 500mgm
 2 bid and
weekly irinotecan 50mgm
 2 in combination with standard
radiotherapy with 50.4Gy (Hofheinz et al, 2005)). Secondary
end points comprise the assessment of the rate of local and
distant failure.
The statistical calculation was made on toxicity issues and was
based on the definition of dose-limiting toxicity (DLT) used in our
previous phase-I trial (Hofheinz et al, 2005). Dose-limiting toxicity
had been defined in this phase-I trial by the occurrence of one
of the following adverse events: grade 4 leukocytopenia/neutro-
penia or thrombocytopenia, symptomatic thrombocytopenia,
grade 3/4 febrile neutropenia, or any Xgrade 3 non-haematolo-
gical adverse events except renal adverse events (Xgrade 2) and
nausea/vomiting.
The rate of DLTs during the present phase-II trial should be
lower than 17% (ie about one out of six patients). With a total of 32
patients, a rate of at least 83% of the patients experiencing no DLTs
during radiochemotherapy can be assumed using Simon’s two-
stage design with a power of 80% and an a-value of 0.2 if less than
five out of 15 (first stage) or eight out of 32 patients (second stage)
experienced DLTs.
Deadline for the follow-up data evaluation was 31 May 2006.
Survival according to Kaplan–Meier was performed using the
Graph-Pad Prism software 4.0 (GraphPad Software, San Diego, CA,
USA). Survival was calculated from the start of study treatment
until patients death or the date of last follow-up. Progression
free-survival was calculated from the start of treatment until the
detection of local recurrence or distant metastases.
RESULTS
Out of 36 patients entering this single-center trial, 33 had newly
diagnosed rectal adenocarcinoma, and three patients had a local
recurrence at the anastomotic site (Table 1). None of these patients
had received prior pelvic radiotherapy. The median distance
from the lower border of the primary to the anal verge was 5cm
(2–15cm). Most tumours were located in the lower third of
the rectum (n¼21 patients). Only five patients had tumours in the
upper third.
Two patients with potentially resectable hepatic metastases and
one patient with suspected pleural carcinomatosis (not histologi-
cally verified) were included in this trial.
Toxicity and dose intensity
Acute toxicity during chemoradiotherapy is listed in Table 2. The
most frequently observed haematologic adverse event was
leucocytopenia. Nine out of 36 patients had grade 3 or 4
leukocytopenia (25%), but no episode of neutropenic fever was
reported. No patient received prophylactic or therapeutic granu-
locyte colony-stimulating factors during the study. Mild thrombo-
cytopenia was only seen in two patients. The median decrease of
haemoglobin level was 2.1gdl
 1 (ranging from 0.0 to 3.5gdl
 1),
but grade 3 or 4 anaemia or major bleeding was not observed.
Of note, no prophylactic measures (eg recombinant human
erythropoetin) were in place and no blood transfusions were
required during chemoradiotherapy.
Table 1 Patient and tumour characteristics
No. of patients 36
Median age (range) 62 years (36–82)
Gender
Male 27
Female 9
ECOG performance status
01 5
11 8
23
Clinical staging
T2 4
T3 26
T4 5
n.a. 1
cN 0 4
cN + 31
n.a. 1
Distant metastases
Resectable (liver) 2
Supected (pleura, irresectable) 1
Distance from lower tumour margin to anal verge
Median 5cm
Range 2–15cm
0–5cm 21
45–10cm 9
410cm 5
NA 1
Table 2 Incidence and maximum toxicity observed during CapIri-RT
treatment (n¼36 patients)
Grade 1 Grade 2 Grade 3 Grade 4
Haematologic
Leucocytopenia 12 7 7 2
Thrombocytopenia 2 — — —
Anaemia 23 9 — —
Gastrointestinal
Nausea/vomiting 9 10 2 —
Mucositis/stomatitis 2 — — —
Diarrhoea 13 15 4 —
Proctitis 11 4 — —
Abdomial cramping 6 4 — —
Laboratory
Hyperbilirubinaemie 2 1 — —
ALAT/ASAT elevation 3 3 1 —
Creatinine elevation 3 — — —
Skin
Hand-foot skin reaction 3 — — —
Alopecia 5 — — —
Radiation dermatits 12 7 — —
Other
Fatigue 11 6 1 —
Cholinergic syndrome 2 — — —
CTC, common toxicity criteria; NCI, National Cancer Institute. Adverse events are
graded according to CTC of the NCI version 2.0.
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Fifteen patients reported diarrhoea grade 2 and four had diarrhoea
grade 3. The median duration of diarrhoea grade 3 was 6 days
(range 3–8 days). Nausea and vomiting grade 3 was observed in
two patients. With respect to laboratory values, increased
activity of transaminases was noted in seven patients and one
patient developed hyperbilirubinaemia grade 2. Moreover, this
latter patient developed grade 4 leucocytopenia, long-lasting
diarrhoea grade 3 over 8 days with marked abdominal cramping
and alopecia. Screening for mutations of the dihydropyrimidine
dehydrogenase enzyme was inconspicuous, but molecular testing
revealed homozygosity for an aberrant UGT1A1 promoter (TA)7/7,
genotype. This disorder is associated with reduced UGT enzyme
activity, impared Sn-38 metabolism, and substantially increased
irinotecan toxicity. Interestingly, this patient had a normal
‘phenotype’ without a history of icterus intermittens (Gilbert-
Meulengracht) or elevation of bilirubine baseline values.
Hand-foot skin reaction was rarely observed owing to the low
doses of capecitabin used and slight alopecia comprised five
patients. Radiation-induced dermatitis affected a total of 19
patients, seven of who had grade 2.
A 42-year-old male patient had a reversible episode of
ventricular fibrillation during physical exercises in the fifth week
of chemoradiation. The resuscitation measures were immediately
successful. Coronary heart disease and electrophysical disorders
were excluded by heart catheterisation. The patient received an
internal implantable heart rhythm converter and defibrillator.
Chemotherapy was stopped, but radiotherapy was continued until
50.4Gy. We speculate that this episode was related to a coronary
spasm due to capecitabine treatment. Interestingly, no further
episodes of ventricular fibrillation were recorded till now.
Four patients had to be hospitalised owing to diarrhoea for a
median of 7 days (range 6–16 days). Radiotherapy was delivered
till a dose of 50.4Gy in all but five patients. Radiotherapy was
terminated in these patients at 39.6Gy (n¼1), 45Gy (n¼3), and
48.6Gy (n¼1) owing to severe fatigue grade 3 (n¼1), diarrhoea
grade 3 (n¼2), and nausea grade 2 and 3 (n¼2).
In all, a total of seven patients developed DLTs according to
prespecified criteria (see Study design and data evaluation). Thus,
a true rate of 83% of the patients experiencing no DLTs during
radiochemotherapy can be assumed with a power of 80% and an
a-value of 0.2.
A median 100% of the scheduled capecitabine dose (range 45–
100%; mean 92%) and a median 95% of the scheduled irinotecan
dose (range 60–100%; mean 91%) was applied. Chemoradiother-
apy was delivered as scheduled in 18 patients, whereas 12 patients
came in need of postponement of chemotherapy (7 days delay
n¼8 patients; 8–14 days n¼4 patients) but received radiotherapy
as scheduled. As mentioned earlier, one patient was withdrawn
from chemotherapy owing to cardiotoxicity but radiotherapy
continued, and chemoradiotherapy was terminated in five patients
for toxicity reasons.
Surgery and pathological features of the resected specimen
Radical TME surgery was scheduled 4–6 weeks after the
termination of the CapIri-RT treatment. Two patients did not
proceed to surgery owing to the presence of metastatic disease
detected immediately before resection (n¼1) and patient refusal
(n¼1). Median time to surgery calculated from the last day of
chemoradiation was 4.7 weeks (range 2.4–11.0 weeks). All but one
patient, who requested surgery after 2.4 weeks owing to personal
reasons, underwent resection at least 4 weeks after the termination
of chemoradiotherapy. Of the 34 surgical procedures, 25 patients
were anterior resections (74%), six patients required abdomino-
perineal resection (18%), and three underwent a Hartmann’s
procedure (8%). Of 23 patients with tumours located in the lower
third of the rectum, 13 had sphincter sparing surgery (57%).
Table 3 illustrates the type of resection in relation to the location of
the primary tumour. All 34 patients had R0-resection with clear
circumferential margins.
Postoperative morbidity comprised prolonged/complicated
wound healing (n¼9; 26%), temporary bowel atonia (n¼8;
24%), anastomotic leakage (n¼3; 12%), and abscess (n¼3; 9%).
Two patients died postoperative owing to septic complica-
tions following anastomotic leakage and pneumonia. Surgery
took place on days 50 and 56 after the termination of
chemoradiotherapy. Of these, one patient developed a systemic
inflammatory syndrome (MRSA infection with endocarditis and
pneumonia) and another patient had acute coronary syndrome,
aspiration and ARDS.
A complete regression of the tumour (pCR; ypT0 N0) was found
in five (15%), and microfoci (few tumour cells scattered within
fibrotic tissue) were found in another nine out of 34 resected
patients. A median of 14 and a total of 456 lymph nodes were
examined. Eleven patients had positive lymph nodes (N1-status
n¼10; N2-status n¼1). Nineteen out of 30 patients with
positive lymph nodes in pretreatment diagnostics were lymph
node negative on pathological examination. T category was
downstaged in 18 of 33 evaluable patients (55%) (Table 4).
The pre-treatment assessment of the T category was made by
endoscopic ultrasound and CT scans, since MRI staging had not
yet become a standard of care in Germany when the present study
concept was designed.
Follow-up, local recurrence and survival The median follow-up is
26.3 months for all 36 patients and 27.6 months (range 16–48
months) for surviving patients.
Thirty-six patients entered the study, of whom 34 proceeded to
surgery. Two of these died postoperatively and three patients
underwent resection of the primary but had irresectable liver or
pleural metastases which were either deemed resectable upon
study entry or uncertain in CT scan. Thus, a total of 29 patients
Table 3 Surgical approach and tumour distance from the anal verge
(n¼34)
Surgical approach (no. of patients)
Tumour
distance from
anal verge
Deep
anterior
resection
Abdomino-
perineal
resection
Hartmann
resection Total
0–5cm 13 6 2 21
45–10cm 7 0 1 8
410cm 5 0 0 5
All tumours 25 6 3 34
Note: The tumor distance could not be calculated in one patient with local relapsed
rectal cancer, and one patient refused surgery.
Table 4 Pathological staging (ypT) compared with clinical staging (cT) at
baseline (n¼33)
No. of patients
ypT0 ypT1 ypT2 ypT3 ypT4 yN+
cT2 (n¼4) — 2 1 1 —
cT3 (n¼26) 4 3 6 11 2
cT4 (n¼3 )1—2— —
cN+ (n¼30) 11
cN  (n¼3) 0
Note: Clinical T- or N- staging was not evaluable in one patient each. Two patients
(including one patient with indeterminable cN status) did not undergo surgery.
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three patients (10.3%) developed distant metastases (lung
and/or pleura n¼2; lymph nodes n¼1). One single patient
developed local recurrence after 15 months and underwent salvage
surgery. Of note, this patient had a ypT4N2 tumour after primary
surgery.
Considering all patients included in this trial, nine out of 36
patients (25%) have died, of whom four succumbed tumour-
related. Among these, two patients had metastases at the time of
diagnosis and one patient had refused potentially curative sugery.
Three patients died non-tumour related (17.7, 29.5, and 39.5
months after the start of therapy).
Considering all patients (n¼36) actuarial calculated overall
survival is 83% at 2 years (patients at risk n¼23), and 78% at 2.5
years (patients at risk n¼15).
DISCUSSION
Several trials on perioperative therapy in rectal cancer have
significantly contributed to a better understanding of an optimized
therapeutic strategy during the past few years. It could be
demonstrated that (i) the best way to deliver radiotherapy is
neoadjuvant (CAO/AIO-ARO-94 trial (Sauer et al, 2004; MRC
CR07 – Sebag-Montefiore et al, 2006), (ii) adding 5-FU to
neoadjuvant radiotherapy improves the pCR and the local
recurrence rates albeit by the price of higher acute toxicity
(EORTC 22921 – Bosset et al, 2005; FFCD 9203 – Gerard et al,
2005), (iii) postoperative 5-FU based adjuvant therapy
might further improve disease-free survival (n.s.) (EORTC 22921
– Bosset et al, 2005). Nevertheless, none of these strategies has
either decreased the rate of distant metastases or led to improved
survival results.
One strategy to improve overall survival and decrease the rate of
distant failure is the intensification of preoperative chemoradia-
tion. By using several drugs during neoadjuvant radiotherapy it is
hoped that the local R0-resection rate further increases and that a
higher amount of distant metastases is eradicated at the earliest
time point. Intensification of postoperative chemotherapy in early-
stage colon cancer patients has already proven to ameliorate the
results of adjuvant treatment. Both the MOSAIC and the NSABP
C-07 trial have unequivocally demonstrated an improved 3-year
disease free survival (DFS) using adjuvant oxaliplatin in combina-
tion with 5-FU/FA regimen for the adjuvant treatment instead of
using 5-FU/FA alone (Andre ´ et al, 2004; Wolmark et al, 2005).
Moreover, the PETACC 3 study reported a 3-year DFS advantage
for an irinotecan/5-FU/FA regimen as well, although this study did
not reach statistical significance, most probably because of an to
an imbalance in risk factors in both treatment arms (van Cutsem
et al, 2005).
In the present phase-II trial we investigated a previously
established regimen using daily capecitabine and weekly irinotecan
in conjunction with 50.4Gy (CapIri-RT – Hofheinz et al, 2005). A
total of 36 patients were treated with this regimen, of whom 34
proceeded to surgery. We found a considerable rate of pCR and
microfoci (14 out of 34 resected patients; 41%), which appears to
be almost doubled in comparison to 5-FU-based chemoradiother-
apy regimen provided that standardised histopathological work-up
is in place. This finding is consistent with data published by
Klautke et al (2006) using a CapIri-RT regimen with some-
what higher doses of capecitabin (750mgm
 2 bid) and irinotecan
(6  weekly 40mgm
 2). A total of seven out of 26 evaluable
patients in this phase I/II trial had pCR or microfoci. Moreover,
using 5-FU and irinotecan, Klautke et al (2005) had previously
observed a rate of 50% of pCR or microfoci in 36 patients
undergoing neoadjuvant chemoradiation. Another trial from
Wales and England – thus far only published as abstract –
confirmes the feasibility of the CapIri-RT regimen using capeci-
tabine 650mgm
 2 in conjunction with irinotecan 60mgm
 2 4
times weekly (Gollins et al, 2006).
With respect to acute toxicity the primary concern of
capecitabine/irinotecan combinations is diarrhoea. The rate of
grade 3–4 diarrhoea reported in the CapIri-RT trials is about
15–30% (Hofheinz et al, 2005; Gollins et al, 2006; Klautke et al,
2006). Using capecitabine and oxaliplatin combinations, grade 3–4
diarrhoea is reported to range between 18% (n¼85; CORE-trial;
Rutten et al, 2006) and 30% (n¼40; RadiOxCape-study; Machiels
et al, 2005). In this cross-trial comparison neither CapIri-RT or
CapOx-RT regimen seem to be advantageous although the use
of different chemotherapy regimen, radiotherapy doses and a
limited number of patients included in these trials preclude
firmer conclusions. The only randomised trial, – published as an
interim analysis at the ASCO meeting 2006, included a total
of 35 patients and used (i) induction chemotherapy with CapOx
and CapIri and (ii) very high doses of irinotecan during
radiochemotherapy (180mgm
 2), which might not be suited
to exploit the radiosensitizing properties of irinotecan (Privitera
et al, 2006).
Major interest should be paid to the rate of surgical complica-
tions after intensified chemoradiotherapy using irinotecan- or
oxaliplatin-based intensified chemoradiotherapy. The limited data
available on surgical morbidity after neoadjuvant intensified
chemoradiation give the impression of an increased rate of
anastomotic leakage by the use of combination regimens. Of
course, trials randomizing between 5-FU- or capecitabine-based
chemoradiation and intensified regimen using additional irinote-
can or oxaliplatin are mandatory to assess the extent of surgical or
late morbidity caused by intensified chemoradiotherapy regimen.
In the present study, we observed a rate of 12% of anastomotic
leakage after deep-anterior resection. Although this rate almost
exactly matches the anastomotic leakage rate in the neoadjuvant
chemoradiotherapy arm of the German rectal cancer trial using
5-FU alone (Sauer et al, 2004) it appears to be high in a single-
centre trial. Clearly, this could be owing to a limited number of
patients in the study. Nonetheless, a thorough reporting of surgical
complications in all studies using intensified chemoradiotherapy
regimen appears to be of great interest. One might speculate
that the price paid for a higher rate of pCR or microfoci obtained
by intensified regimens is a higher risk of surgical morbidity,
for example, anastomotic leakage. We therefore, advocate for a
detailed reporting of surgical morbidity in all trials on intensified
chemoradiotherapy.
With regard to long-term outcome, we observed only one local
recurrence (a patient with ypT4N2 at surgery) after a median
observation time of 28 months in surviving patients, suggesting
a high rate of local control. Five patients developed distant
metastases. The actuarial 2-year survival for all 36 patients is 83%
(2.5-year survival 78%). Similarly, data on 36 patients receiving
irinotecan/5-FU-based chemoradiotherapy published after a med-
ian follow-up of 40 months suggest that irinotecan-based regimen
might provide superior long term results (4-year local recurrence
rate 7% and disease-specific survival of 70%; Klautke et al, 2005).
Clearly, larger (randomized) trials and longer follow-up periods
are needed.
In all, the CapIri-RT regimen appears to be safe resulting
in a rate of about 40% of patients with pCR or microfoci at
surgery. Larger trials and longer follow-up are awaited in order
to assess the real impact of the higher remission rate on
long-term results. Another important issue to be adressed in
prospective trials is, whether or to which extent intensified
regimen compromise the safety of surgery. After years of
stagnation in the treatment of rectal cancer intensified neo-
adjuvant and/or adjuvant combination chemo(radio)therapy
regimens using newer cytostatics and maybe targeted therapies
clearly hold the promise to further improve the treatment of
this disease.
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